Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Apr 27, 2023 AURORA, Colo., April 27, 2023 /PRNewswire/ — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University… Read the full article […]
Molecular Designs releases their new Simplicity™ Gastrointestinal Pathogen Panel
Apr 11, 2023 BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ — Molecular Designs, a developer and manufacturer of molecular infectious disease assays, announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections. Simplicity Panels are pre-pipetted, polymerase chain reaction (PCR) assays provided in a unique breakaway […]
Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference
Apr 04, 2023 AURORA, Colo., April 4, 2023 /PRNewswire/ — Foresight Diagnostics, a leader in molecular cancer diagnostics, announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR)… Read the full article on PR Newswire.
Factorial Biotechnologies collaborates with Watchmaker Genomics to dramatically simplify single-cell sequencing
Mar 28, 2023 SAN CARLOS, Calif., March 28, 2023 /PRNewswire/ — Factorial Biotechnologies, an emerging single-cell sequencing company with a novel intracellular library preparation technology, has announced a collaboration with Watchmaker Genomics, a life sciences company that specializes in developing high-stringency applications for reading, writing, and editing of DNA and RNA… Read the full article on […]
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Aug 31, 2022 Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and […]
Foresight Diagnostics Announces the Hiring of Sandra Close, Ph.D., as Chief Operations Officer
Apr 04, 2022 Foresight Diagnostics today announced the hiring of Sandra Close, Ph.D., as Chief Operations Officer (COO). Sandra brings extensive experience in delivering drugs and diagnostics, with a focus on organizational structure, business strategy, and quality and regulatory requirements. Dr. Close has served as an executive leader in both diagnostic and pharmaceutical companies, including […]
YDS Pharmatech Helps Uncover a Novel Viral Recognition Pathway: Published in Nature Chemical Biology
Aug 18, 2022 YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today. The publication was co-authored by Xing Che, Ph.D., founder and CEO of YDS Pharmatech, and by researchers at Tianjin Medical University led by Prof. Heng Zhang. The company helped reveal a new viral protein […]
A Digital Assay to Streamline PD-L1 IHC: Published in Scientific Reports
Jun 14, 2022 Flagship Biosciences, Inc., today announced the publication of a paper describing validation of a novel digital spatial biology assay in Scientific Reports. The assay, Tissue Insight (TI) 22C3 NSCLC, surpasses manual scoring in PD-L1 positive tumor samples. Modern cancer immunotherapy for non-small cell lung cancer (NSCLC) utilizes programmed death-ligand 1 (PD-L1) checkpoint […]
DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus
Jun 09, 2022 DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity’s test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE […]
DxTerity Diagnostics Begins Enrollment in the ELEVATE Clinical Study for Lupus
May 27, 2022 LOS ANGELES, May 27, 2022 /PRNewswire/ — DxTerity Diagnostics today announced the opening of enrollment in ELEVATE (Empower Lupus Erythematous Patients Via Allowing RemoTe Evaluation), a new observational clinical study for patients with Systemic Lupus Erythematosus (SLE or lupus). The study opening aligns with Lupus Awareness Month (May) and efforts to advance precision medicine and improve the lives of patients […]